Related Experiment Video
Updated: Jan 21, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.6K
Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
Solène Fernandez1,2, Vanessa Desplat1,2, Arnaud Villacreces1,2
1Institut National de la Santé et de la Recherche Médicale, U1035 Bordeaux, France.
International Journal of Molecular Sciences
|July 25, 2019
Summary
Targeted therapies, like tyrosine kinase inhibitors (TKIs), are revolutionizing acute myeloid leukemia (AML) treatment by targeting specific molecular mutations. This review explores the history and development of TKIs for AML, offering new hope beyond conventional chemotherapy.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute myeloid leukemia (AML) is a complex blood cancer characterized by abnormal myeloid cell proliferation and blocked differentiation.
- The traditional '3 + 7' chemotherapy regimen faces challenges due to AML's molecular heterogeneity.
- Specific mutations, such as in the FLT3 receptor, are common in AML and drive disease progression.
Purpose of the Study:
- To review the historical development of targeted therapies for AML.
- To discuss the role of tyrosine kinase inhibitors (TKIs) in AML treatment.
- To highlight the impact of molecular profiling on therapeutic strategies.
Main Methods:
- Literature review of scientific publications and clinical trials.
- Analysis of molecular targets in acute myeloid leukemia.
- Examination of the evolution of targeted therapies, including TKIs.
Main Results:
- FLT3 receptor alterations (overexpression or mutation) occur in a significant proportion of AML cases.
- Targeted therapies, particularly TKIs, have emerged as promising treatments for AML.
- The molecular landscape of AML enables combination strategies with conventional chemotherapy.
Conclusions:
- Targeted therapies offer a personalized approach to AML treatment based on individual molecular profiles.
- TKIs represent a significant advancement in AML therapy, addressing specific driver mutations.
- Future AML treatment will likely involve integrating targeted agents with chemotherapy.
Related Concept Videos
01:26Receptor Tyrosine Kinases
18.2K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.2K
02:54Protein Kinases and Phosphatases
15.0K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.0K
02:54Protein Kinases and Phosphatases
4.4K
4.4K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
462
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
462
01:15Differentiation of Common Myeloid Progenitor Cells
3.9K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.9K
01:25cAMP-dependent Protein Kinase Pathways
8.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.4K